Technetium Radiopharmaceuticals contain the ideal radionuclide technetium-99m and are used in more than 80% of nuclear medicine procedures. This radiometal does not emit particles, only gamma radiation (photon energy of 140 keV) and 10% of internal conversion. The half-life is 6 hours, obtained from a generator system’s parent molybdenum-99 (half-life = 67 hours).
The generator absorbs the molybdenum activity onto the alumina column, followed by the elution of saline to give technetium-99m labelled sodium pertechnetate. After intravenous injection, technetium-99m pertechnetate is reversibly bound to protein and rapidly leaves the plasma compartment.
Nevertheless, over 50% of the activity leaves the plasma within several minutes and is distributed in the extracellular fluid. These technetium radiopharmaceuticals concentrate in the salivary and thyroid glands, including the gastric mucosa and the choroid plexus cells, produced in the cerebrospinal fluid in the brain’s ventricles. Excretion of the activity is by either the gastrointestinal or the renal route.
Technetium-99m pertechnetate is localised by the thyroid similarly to iodides but is not incorporated into thyroglobulin. The imaging agent technetium-99m tetrofosmin, known as Myoview, has good myocardial uptake, typically 1-2% of the injected dose, with a first-pass extraction efficiency of approximately 50%. In addition, Myoview has good retention and minimal redistribution from the myocardium over time.
The myocardium, parathyroid, and breast tissue also absorb technetium-99 m sestamibi. Subsequently, single-photon emission computed tomography (SPECT) is performed to detect the gamma rays emitted by the decay of technetium-99m. In its kit form, sestamibi is used to detect coronary artery disease (CAD) by accumulating in the myocardial ischemia to gain information for patient management decisions.
You are here:
home »
Unconjugated radionuclides offer unique advantages in nuclear medicine, enabling precise imaging and targeted therapies.
Powering Precision: The Untapped Potential of Unconjugated Radionuclides Read Post »
This article examines the cancer risks associated with radionuclide administration in medical treatments and strategies for mitigation.
Assessing the Cancer Risk in Patients Administered Radionuclides Read Post »
What are radiopharmaceuticals? They are radioactive drugs used for diagnosing and treating various medical conditions.
What are Radiopharmaceuticals? An Insight into Their Role and Applications Read Post »
Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy.
Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer Read Post »
Radiopharmaceuticals play a crucial role in heart imaging, enabling accurate diagnosis and effective treatment of various cardiac conditions.
Radiopharmaceuticals in Heart Imaging for Diagnosis and Treatment Read Post »
SPECT imaging, by combining functional and anatomical insights, significantly enhances diagnostic accuracy in various medical fields.
The Future of SPECT Imaging and Emerging Technological Advances Read Post »
Technetium-99m and Radium-223 are pivotal in managing bone metastases, enhancing both diagnostic accuracy and therapeutic efficacy.
In Brazil, the growing radiopharmaceutical market, driven by chronic disease and advanced imaging technologies, is becoming increasingly significant in healthcare.
Advancing Healthcare: The Dynamic Growth of Brazil’s Radiopharmaceutical Market Read Post »
Lymphoseek offers targeted, efficient sentinel lymph node mapping, improving cancer staging and reducing surgical morbidity.
Technetium-99m tetrofosmin is vital for detecting coronary artery disease via myocardial perfusion imaging, enhancing cardiac care.
Technetium-99m succimer is pivotal for renal imaging, enhancing diagnostics with minimal invasiveness and low radiation.
Technetium-99m UltraTag RBCs enhance blood pool imaging and precisely localize gastrointestinal bleeding in non-invasive diagnostic procedures.
Technetium-99m pyrophosphate is pivotal for diagnosing bone diseases and cardiac amyloidosis through targeted radiopharmaceutical imaging.
Technetium-99m Pyrophosphate (Technescan PYP) in Bone Imaging and Cardiac Imaging Read Post »
Technetium-99m pentetate revolutionises brain and kidney imaging by providing crucial non-invasive insights into their function.
Tc-99m MAG3 scintigraphy offers unparalleled insights into renal function, aiding diagnosis and management of kidney disorders.
Technetium-99m Mebrofenin is pivotal for hepatobiliary imaging, assessing liver function, gallbladder diseases, and biliary obstructions.
Tc-99m MAA is pivotal in hepatobiliary imaging, providing crucial functional insights into liver and gallbladder health.
Technetium-99m exametazime (Ceretec) is a pivotal radiopharmaceutical in nuclear medicine, revolutionising brain imaging with high precision and reliability.
Technetium-99m bicisate (Neurolite) facilitates stroke diagnosis by enabling cerebral perfusion imaging, aiding in locating affected brain regions.
The most commonly used medical radioisotope in diagnostic procedures is technetium-99m.
What is myocardial perfusion imaging of the heart? Read Post »
